Patent: 10,383,930

Try a free trial

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,383,930

Title:	Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
Abstract:	A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.
Inventor(s):	Mahr; Andrea (Tubingen, DE), Weinschenk; Toni (Aichwald, DE), Schoor; Oliver (Tubingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Munchen Schwabing, DE), Muller; Phillip (Kassel, DE), Leibold; Julia (Langkampfen, AT), Goldfinger; Valentina (Tubingen, DE)
Assignee:	IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)
Application Number:	16/100,498
Patent Claims:	see list of patent claims

Details for Patent 10,383,930

Glossary

Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	001	2004-02-26	Try a Free Trial	IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)	2035-08-06	RX		search
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	002	2004-02-26	Try a Free Trial	IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)	2035-08-06	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.